Hsbc Holdings PLC Lowers Position in NeoGenomics, Inc. $NEO

Hsbc Holdings PLC cut its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 36.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,769 shares of the medical research company’s stock after selling 10,800 shares during the period. Hsbc Holdings PLC’s holdings in NeoGenomics were worth $173,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of NEO. Northern Trust Corp grew its holdings in shares of NeoGenomics by 7.4% in the fourth quarter. Northern Trust Corp now owns 1,621,809 shares of the medical research company’s stock valued at $26,727,000 after acquiring an additional 111,170 shares in the last quarter. Graham Capital Management L.P. grew its holdings in shares of NeoGenomics by 467.5% in the fourth quarter. Graham Capital Management L.P. now owns 62,669 shares of the medical research company’s stock valued at $1,033,000 after acquiring an additional 51,626 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of NeoGenomics by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,544 shares of the medical research company’s stock valued at $1,196,000 after acquiring an additional 2,724 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of NeoGenomics by 44.5% in the fourth quarter. ProShare Advisors LLC now owns 38,445 shares of the medical research company’s stock valued at $634,000 after acquiring an additional 11,831 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC bought a new position in shares of NeoGenomics in the fourth quarter valued at approximately $183,000. 98.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

NEO has been the subject of several recent analyst reports. Morgan Stanley set a $8.00 target price on NeoGenomics and gave the company an “equal weight” rating in a report on Wednesday, July 30th. Guggenheim started coverage on NeoGenomics in a report on Thursday, May 15th. They set a “neutral” rating for the company. William Blair reaffirmed a “market perform” rating on shares of NeoGenomics in a report on Tuesday, July 29th. Stephens increased their price objective on NeoGenomics from $6.50 to $11.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Needham & Company LLC increased their price objective on NeoGenomics from $8.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, August 29th. Five research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $13.22.

NeoGenomics Price Performance

NEO stock opened at $7.98 on Friday. The firm has a 50 day moving average price of $6.71 and a 200-day moving average price of $8.03. NeoGenomics, Inc. has a 52-week low of $4.72 and a 52-week high of $19.11. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -9.85 and a beta of 1.62. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.58 and a current ratio of 3.92.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.